COVID-19-associated nausea and vomiting

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

WikiDoc Resources for COVID-19-associated nausea and vomiting
Articles
Most recent articles on COVID-19-associated nausea and vomiting Most cited articles on COVID-19-associated nausea and vomiting Review articles on COVID-19-associated nausea and vomiting Articles on COVID-19-associated nausea and vomiting in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated nausea and vomiting Images of COVID-19-associated nausea and vomiting Photos of COVID-19-associated nausea and vomiting Podcasts & MP3s on COVID-19-associated nausea and vomiting Videos on COVID-19-associated nausea and vomiting
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated nausea and vomiting Bandolier on COVID-19-associated nausea and vomiting TRIP on COVID-19-associated nausea and vomiting
Clinical Trials
Ongoing Trials on COVID-19-associated nausea and vomiting at Clinical Trials.gov Trial results on COVID-19-associated nausea and vomiting Clinical Trials on COVID-19-associated nausea and vomiting at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated nausea and vomiting NICE Guidance on COVID-19-associated nausea and vomiting NHS PRODIGY Guidance FDA on COVID-19-associated nausea and vomiting CDC on COVID-19-associated nausea and vomiting
Books
Books on COVID-19-associated nausea and vomiting
News
COVID-19-associated nausea and vomiting in the news Be alerted to news on COVID-19-associated nausea and vomiting News trends on COVID-19-associated nausea and vomiting
Commentary
Blogs on COVID-19-associated nausea and vomiting
Definitions
Definitions of COVID-19-associated nausea and vomiting
Patient Resources / Community
Patient resources on COVID-19-associated nausea and vomiting Discussion groups on COVID-19-associated nausea and vomiting Patient Handouts on COVID-19-associated nausea and vomiting Directions to Hospitals Treating COVID-19-associated nausea and vomiting Risk calculators and risk factors for COVID-19-associated nausea and vomiting
Healthcare Provider Resources
Symptoms of COVID-19-associated nausea and vomiting Causes & Risk Factors for COVID-19-associated nausea and vomiting Diagnostic studies for COVID-19-associated nausea and vomiting Treatment of COVID-19-associated nausea and vomiting
Continuing Medical Education (CME)
CME Programs on COVID-19-associated nausea and vomiting
International
COVID-19-associated nausea and vomiting en Espanol COVID-19-associated nausea and vomiting en Francais
Business
COVID-19-associated nausea and vomiting in the Marketplace Patents on COVID-19-associated nausea and vomiting
Experimental / Informatics
List of terms related to COVID-19-associated nausea and vomiting

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Synonyms and keywords:

Historical Perspective

• The etiological agent is SARS-CoV-2, named for the similarity of its symptoms to those induced by the severe acute respiratory syndrome, causing coronavirus disease 2019 (COVID-19), is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
• The growing number of patients however, suggest that human-to-human transmission is actively occurring.
• The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.
• On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.

Classification

There is no established system for the classification of nausea and vomiting in COVID-19.

Pathophysiology

• SARS-CoV-2 uses the Angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 receptors for cell entry. These receptors are presently abundantly not only in the lungs but also in the enterocytes of the small intestine. Other sites of expression of the receptors in the gastrointestinal tract are-the upper esophagus, liver, and colon.
• Entry of the virus causes disruption of the enterocytes and may lead to inflammation and alteration of intestinal permeability.
• The gastrointestinal symptoms of COVID-19 are thought to arise due to the invasion of enterocytes.

Causes

Disease name] may be caused by [cause1], [cause2], or [cause3].

OR

Common causes of [disease] include [cause1], [cause2], and [cause3].

OR

The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].

OR

The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.

Differentiating ((Page name)) from other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Epidemiology and Demographics

• According to a study by Redd et al, the prevalence of nausea in COVID-19 patients was 26%.

The more common GI symptoms were-

• Anorexia- 35 %
• Diarrhea- 34 %

• Another study by Luo et al reported that 16% of patients presented with GI symptoms like diarrhea, nausea, vomiting without any respiratory symptoms.

Risk Factors

Some gastrointestinal factors may predispose patients to infection with COVID-19.

• Inflammatory bowel disease patients- due to use to glucocorticoids, but not TNF-alpha inhibitors
• Increasing age
• Other comorbidities
• Use of glucocorticoids

Screening

There is insufficient evidence to recommend routine screening.

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

• Infectious virions released from the GI tract can be monitored by real-time reverse transcriptase polymerase chain reaction (rRT-PCR)
• A study by Xiao et al assessed the clinical significance of measuring SARS-CoV-2 RNA in the feces.
• The fecal test remained positive until 12 days after the disease onset in patients with diarrhea.
• Notably, stool test for viral RNA remained positive despite negative respiratory tests. This suggests the possibility of gastrointestinal transmission via the fecal-oral route despite clearance from the respiratory tract.
• It was recommended transmission-based precautions for hospitalized COVID-19 patients should be continued till the rRT-PCR for SARS-CoV-2 turns negative.

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

Template:WikiDoc Sources